

ABSTRACT OF THE DISCLOSURE

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having
5 specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or
10 polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

"Express Mail" mailing label number EL307940916US
Date of Deposit August 9 1999
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231.

Adriane M. Baird
(printed name)

Adriane M. Baird
(Signature)